Interestingly, the combination therapy exhibited marked antitumor efficacy in these HCC murine models (Fig. 6g–k and Supplementary Fig. S10a–h) and altered the immune landscape toward antitumor immunity, with decreased proportions of Tregs and MDSCs and increased proportions of IFN-γ+ and granzyme B+ CD8+ T cells (Fig. 6l–m). Here, CD8A is linked to hepatocellular carcinoma.